Disease · HP_0012418
Hypoxemia
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. Hypoxemia. Diseases, record HP_0012418. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0012418
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Hypoxemia
- Open Targets ID
- HP_0012418
- Other names
- Low blood oxygen level
- Highest stage of its drugs
- Phase 3, for 2 of its 26 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs26
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| NITRIC OXIDE | CHEMBL1200689 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| DOXAPRAM | CHEMBL1754 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FOSTAMATINIB | CHEMBL2103830 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| HEPARIN | CHEMBL4650299 | Oligosaccharide | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ICATIBANT | CHEMBL2028850 | Protein | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NALOXONE | CHEMBL80 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ALBUTEROL | CHEMBL714 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ASCORBIC ACID | CHEMBL196 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PEGINTERFERON LAMBDA-1A | CHEMBL2108723 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| SODIUM CHLORIDE | CHEMBL1200574 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 26
See all 26 drugsTargets71
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| GABRA1 | GABA-A receptor; anion channel | 6 | GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator | Phase 1/2 | https://conductscience.org/library/genes/2554 | Drugs and targets |
| GABRA2 | GABA-A receptor; anion channel | 6 | GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator | Phase 1/2 | https://conductscience.org/library/genes/2555 | Drugs and targets |
| GABRA3 | GABA-A receptor; anion channel | 6 | GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator | Phase 1/2 | https://conductscience.org/library/genes/2556 | Drugs and targets |
| GABRA4 | GABA-A receptor; anion channel | 6 | GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator | Phase 1/2 | https://conductscience.org/library/genes/2557 | Drugs and targets |
| GABRA5 | GABA-A receptor; anion channel | 6 | GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator | Phase 1/2 | https://conductscience.org/library/genes/2558 | Drugs and targets |
| GABRA6 | GABA-A receptor; anion channel | 6 | GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator | Phase 1/2 | https://conductscience.org/library/genes/2559 | Drugs and targets |
| GABRB1 | GABA-A receptor; anion channel | 6 | GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator | Phase 1/2 | https://conductscience.org/library/genes/2560 | Drugs and targets |
| GABRB2 | GABA-A receptor; anion channel | 6 | GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator | Phase 1/2 | https://conductscience.org/library/genes/2561 | Drugs and targets |
| GABRB3 | GABA-A receptor; anion channel | 6 | GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator | Phase 1/2 | https://conductscience.org/library/genes/2562 | Drugs and targets |
| GABRD | GABA-A receptor; anion channel | 6 | GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator | Phase 1/2 | https://conductscience.org/library/genes/2563 | Drugs and targets |
1 to 10 of 71
See all 71 targetsTrials24
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00310401 | The Effect of Nebulized Albuterol on Donor Oxygenation | Phase 2 | 506 | 2013-09-02 | Brain Death, Organ Donor, Pulmonary Edema | ALBUTEROL, SODIUM CHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02581111 | Naloxone for Optimizing Hypoxemia Of Lung Donors | Phase 2/3 | 199 | 2018-10-16 | Brain Death, Organ Donors, Lung Transplantation | NALOXONE | Its record names the disease | ClinicalTrials.gov |
| NCT04344184 | SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI) | Phase 2 | 47 | 2024-04-04 | COVID-19, Lung Injury, Acute, Kidney Injury | ASCORBIC ACID | Its record names the disease | ClinicalTrials.gov |
| NCT05593770 | International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response | Phase 2/3 | 28 | 2024-11-05 | COVID-19, SARS-CoV2 Infection, Coronavirus Infection | FOSTAMATINIB | Its record names the disease | ClinicalTrials.gov |
| NCT05289570 | Voxelotor for Improving Oxygen Saturation in Adults | Phase 2 | 3 | 2024-07-24 | Acute Lung Injury, End Stage Lung Disease | VOXELOTOR | Its record names the disease | ClinicalTrials.gov |
| NCT07079176 | Etomidate Combined With Propofol Versus Propofol for Sedation in High-Altitude Patients During Gastroscopy: a Randomized Multicenter Clinical Trial | Not applicable | 732 | Gastrointestinal Endoscopy | ETOMIDATE, PROPOFOL | Its record names the disease | ClinicalTrials.gov | |
| NCT06187896 | The Effects of Remimazolam on the Incidence of Severe Hypoxia During Sedated Hysteroscopy for Assisted Reproduction in Overweight or Obese Patients | Not applicable | 600 | Hypoxia, Hysteroscopy, Overweight or Obesity | PROPOFOL, REMIMAZOLAM | Its record names the disease | ClinicalTrials.gov | |
| NCT07187765 | Respiratory Safety of Oliceridine During Sedated Gastrointestinal Endoscopy | Not applicable | 508 | Hypoxemia During Surgery, Gastrointestinal Endoscopy | OLICERIDINE, SUFENTANIL | Its record names the disease | ClinicalTrials.gov | |
| NCT04430790 | Doxapram Therapy in Preterm Infants (DOXA Trial) | Phase 3 | 396 | Apnea of Prematurity, Respiratory Insufficiency | DOXAPRAM | Its record names the disease | ClinicalTrials.gov | |
| NCT04807413 | Nitric Oxide During Cardiopulmonary Bypass in Adult Surgery | Phase 3 | 300 | Hypoxia | NITRIC OXIDE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 24
See all 24 trialsComparisons in its trials16
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Albuterol vs Saline: Number of Donor Lungs Used for Transplantation | 74 of 260 | 78 of 246 | 506 | NCT00310401 | Trial comparisons |
| Albuterol vs Saline: serious adverse events | 0 of 260 | 0 of 246 | 506 | NCT00310401 | Trial comparisons |
| Naloxone vs Placebo: Number of Participants Who Had Lungs Transplanted | 19 of 98 | 19 of 101 | 199 | NCT02581111 | Trial comparisons |
| Naloxone vs Placebo: deaths from any cause | 0 of 98 | 0 of 101 | 199 | NCT02581111 | Trial comparisons |
| Naloxone vs Placebo: serious adverse events | 0 of 98 | 0 of 101 | 199 | NCT02581111 | Trial comparisons |
| Infusion vs Placebo: deaths from any cause | 5 of 22 | 7 of 25 | 47 | NCT04344184 | Trial comparisons |
| Infusion vs Placebo: serious adverse events | 0 of 22 | 1 of 25 | 47 | NCT04344184 | Trial comparisons |
| Fostamatinib vs Placebo: deaths from any cause | 1 of 14 | 3 of 14 | 28 | NCT05593770 | Trial comparisons |
| Fostamatinib vs Placebo: serious adverse events | 8 of 14 | 5 of 14 | 28 | NCT05593770 | Trial comparisons |
| Fostamatinib vs Placebo: 28-day Mortality | 1 of 13 | 1 of 12 | 25 | NCT05593770 | Trial comparisons |
1 to 10 of 16
See all 16 comparisons in its trialsPapers from its trials37
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0012418
GET https://conductscience.org/api/diseases/v1/HP_0012418/drugs?page=2